Skip to main content

biotech_innovation

Matica Bio Partners With Bondwell to Advance Texas Bioprocessing Tech

Matica Bio Partners With Bondwell to Advance Texas Bioprocessing Tech

College Station, Texas – September 13, 2026 -- Matica Biotechnology, a Texas-based cell and gene therapy CDMO, has entered a collaboration with Bondwell Technologies to advance the latter's proprietary protein bioprocessing platform toward manufacturing readiness.

Matica Bio will provide development expertise to prepare Bondwell's technology for commercialization

Under the agreement, Matica Bio will support Bondwell Technologies, headquartered in College Station, in scaling its proprietary protein technology for bioprocessing and life science applications. The collaboration is designed to move Bondwell's platform closer to manufacturing readiness and future commercial deployment.

Rznomics Boosts Circular RNA Yield 7-Fold, Beats PIE Method 2x

Rznomics Boosts Circular RNA Yield 7-Fold, Beats PIE Method 2x

Seongnam, South Korea – September 09, 2026 -- Rznomics Inc. (KOSDAQ: 476830) has achieved up to a seven-fold increase in circular RNA (circRNA) production efficiency through engineering upgrades to its proprietary Self-Targeting and Splicing (STS) platform, according to peer-reviewed research published in Nucleic Acids Research on September 4, 2026.

Optimized STS method doubles circularization efficiency versus industry-standard PIE technique

In tests using Factor VIII RNA measuring approximately 7.8 kilo-nucleotides in length, the upgraded STS approach delivered roughly twice the circularization efficiency of the widely used Permuted Intron–Exon (PIE) method, a standard benchmark in circRNA manufacturing. The finding directly addresses a persistent industry constraint: circularization efficiency typically drops as RNA length increases, limiting the size of genes that can be produced at commercial scale.